ライフサイエンスコーパス: xemilofiban

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 d (P < or = .029) platelet aggregation after xemilofiban.

2 ) by xemilofiban > or =2.5 mg/kg, HD ASA, or xemilofiban 1.25 mg/kg plus HD ASA compared with placebo

3 These doses of xemilofiban or xemilofiban 1.25 mg/kg plus HD ASA increased time to occ

4 Xemilofiban > or =2.5 mg/kg or xemilofiban 1.25 mg/kg plus HD ASA significantly increas

5 Xemilofiban > or =2.5 mg/kg but not xemilofiban 1.25 mg/kg plus HD ASA significantly increas

6 Xemilofiban > or =2.5 mg/kg, HD ASA, or xemilofiban 1.25 mg/kg plus HD ASA significantly reduced

7 ith xemilofiban > or =2.5 mg/kg but not with xemilofiban 1.25 mg/kg plus HD ASA.

8 Conscious dogs were treated with xemilofiban (1.25, 2.5, 5.0, or 6 mg/kg, n=6); low-dose

9 with placebo), and 306 who received 20 mg of xemilofiban (12.7 percent, P=0.36 for the comparison wit

10 te, 13.5 percent), 332 who received 10 mg of xemilofiban (13.9 percent, P=0.82 for the comparison wit

11 interventions were randomized to placebo or Xemilofiban 35 mg orally before and 20 to 25 mg TID for

12 red over time after the first dose of either xemilofiban (5, 10, 15, or 20 mg) or placebo (ticlopidin

13 ing pharmacokinetic/pharmacodynamic study of xemilofiban, a new oral nonpeptide GP IIb/IIIa antagonis

14 ter, placebo-controlled, randomized trial of xemilofiban, an oral platelet GP IIb/IIIa blocking agent

15 g, single-blind, placebo-controlled trial of xemilofiban, an oral platelet GP IIb/IIIa receptor antag

16 Xemilofiban, an orally active glycoprotein IIb/ IIIa rec

17 cluding Integrelin, Tirofiban, Lamifiban and Xemilofiban, are specific in binding to this particular

18 tion of the glycoprotein IIb/IIIa antagonist xemilofiban before percutaneous coronary revascularizati

19 Plasma levels of xemilofiban correlated with the degree of platelet inhib

20 Patients on Xemilofiban for 30 days reported episodes of mild mucocu

21 ists (abciximab, tirofiban, eptifibatide, or xemilofiban) from platelets does not result in platelet

22 at 2 and 4 weeks was 15%, 8%, and 11% in the Xemilofiban group compared with 80%, 68%, and 69% in the

23 BT was increased (P<0.05) with xemilofiban > or =2.5 mg/kg but not with xemilofiban 1.2

24 Xemilofiban > or =2.5 mg/kg but not xemilofiban 1.25 mg/

25 Xemilofiban > or =2.5 mg/kg or xemilofiban 1.25 mg/kg pl

26 idence of thrombosis was reduced (P<0.05) by xemilofiban > or =2.5 mg/kg, HD ASA, or xemilofiban 1.25

27 Xemilofiban > or =2.5 mg/kg, HD ASA, or xemilofiban 1.25

28 were randomized to receive either placebo or xemilofiban in a dose of 15 or 20 mg.

29 Oral xemilofiban in doses of > or = 10 mg produced > or = 50%

30 ive placebo (250 mg ticlopidine P.O. BID) or xemilofiban in doses of 5, 10, 15, or 20 mg P.O. BID.

31 The pharmacodynamic efficacy of xemilofiban-induced platelet inhibition and clinical saf

32 Xemilofiban inhibited platelet aggregation and was well

33 Xemilofiban inhibited platelet aggregation to both ADP a

34 e randomly assigned to receive 20 mg of oral xemilofiban or placebo 30 to 90 minutes before undergoin

35 on, with maintenance doses of 10 or 20 mg of xemilofiban or placebo administered three times daily fo

36 These doses of xemilofiban or xemilofiban 1.25 mg/kg plus HD ASA increa

37 Xemilofiban produced a rapid, sustained, marked inhibiti

38 Doses of xemilofiban required to achieve > or = 50% inhibition of

39 Oral xemilofiban resulted in a dose-dependent inhibition of p

40 We report on the antithrombotic effect of xemilofiban (SC-54684A), an oral GP IIb/IIIa antagonist,

41 mab who received the highest dose (20 mg) of xemilofiban studied.

42 Among 20 patients randomized to Xemilofiban there was 1 death after emergency coronary b

43 A significant dose-response relationship to xemilofiban was observed.

44 ervention and who were randomized to receive xemilofiban were administered a reduced dosage (10 mg TI

45 the duration of pharmacodynamic response to xemilofiban were enhanced by prior abciximab treatment.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。